Dainippon Sumitomo To Launch Diabetes Drug Surepost
This article was originally published in PharmAsia News
Executive Summary
Dainippon Sumitomo Pharma will launch rapid-acting insulin Surepost (repaglinide) in Japan May 16. The insulin is the third in its class in Japan, after Fastic (nateglinide) from Ajinomoto/Astellas Pharma Inc., and Glufast (mitiglinide) from Kissei Pharmaceutical. (Click here for more - Japanese language
You may also be interested in...
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.